T1	PROC 44 69	Profilaxis tromboembólica
T2	CHEM 74 82	apixabán
#1	AnnotatorNotes T2	C1831808; apixaban; Organic Chemical · Pharmacologic Substance
T3	DISO 100 116	mieloma múltiple
#2	AnnotatorNotes T3	C0026764; Multiple Myeloma; Neoplastic Process
T4	PROC 126 137	diagnóstico
#3	AnnotatorNotes T4	C0011900; Diagnosis; Diagnostic Procedure
T5	PROC 151 161	trasplante
#4	AnnotatorNotes T5	C0040732; Transplantation; Therapeutic or Preventive Procedure
T6	CHEM 216 242	fármacos inmunomoduladores
T7	PROC 265 275	Profilaxis
#5	AnnotatorNotes T7	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T8	PROC 529 553	consentimiento informado
#6	AnnotatorNotes T8	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T9	PROC 555 557	CI
#7	AnnotatorNotes T9	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T10	PROC 607 621	procedimientos
#8	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T11	PROC 715 729	diagnosticados
#9	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	DISO 741 769	mieloma múltiple sintomático
T13	PROC 780 791	tratamiento
#10	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 839 849	trasplante
#11	AnnotatorNotes T14	C0040732; Transplantation; Therapeutic or Preventive Procedure
T15	PROC 889 903	diagnosticados
#12	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 907 938	leucemia de células plasmáticas
#13	AnnotatorNotes T16	C0023484; Leukemia, Plasma Cell; Neoplastic Process
T17	DISO 940 971	macroglobulinemia de Waldeström
T18	DISO 973 987	síndrome POEMS
#14	AnnotatorNotes T18	C0085404; POEMS Syndrome; Disease or Syndrome
T19	DISO 990 1020	amiloidosis de cadenas ligeras
#15	AnnotatorNotes T19	C4509023; Light chain (AL) amyloidosis; Disease or Syndrome
T20	DISO 1033 1048	MM asintomático
T21	DISO 1055 1100	gammapatía monoclonal de significado incierto
#16	AnnotatorNotes T21	C0026470; Monoclonal Gammopathy of Undetermined Significance; Neoplastic Process
T22	PROC 1135 1146	tratamiento
#17	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 1240 1250	trasplante
#18	AnnotatorNotes T23	C0040732; Transplantation; Therapeutic or Preventive Procedure
T24	PROC 1304 1325	método anticonceptivo
#19	AnnotatorNotes T24	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T25	DISO 1403 1424	neuropatía periférica
#20	AnnotatorNotes T25	C0031117; Peripheral Neuropathy; Disease or Syndrome
T26	DISO 1447 1450	ETV
T27	DISO 1466 1476	Hemorragia
#21	AnnotatorNotes T27	C0019080; Hemorrhage; Pathologic Function
T28	DISO 1501 1509	sangrado
#22	AnnotatorNotes T28	C0019080; Hemorrhage; Pathologic Function
T29	PROC 1526 1552	tratamiento anticoagulante
#23	AnnotatorNotes T29	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T30	CHEM 1555 1568	antiagregante
#24	AnnotatorNotes T30	C0085826; Antiplatelet Agents; Pharmacologic Substance
T31	PROC 1597 1622	profilaxis anticoagulante
T32	DISO 1671 1686	Trombocitopenia
#25	AnnotatorNotes T32	C0040034; Thrombocytopenia; Disease or Syndrome
T33	DISO 1970 1973	VHB
#26	AnnotatorNotes T33	C0019163; Hepatitis B; Disease or Syndrome
T34	PROC 1777 1803	Aclaramiento de creatinina
#27	AnnotatorNotes T34	C0373595; Creatinine clearance measurement; Laboratory Procedure
T35	DISO 1818 1839	Hipertensión arterial
#28	AnnotatorNotes T35	C0020538; Hypertensive disease; Disease or Syndrome
T36	PROC 1939 1949	Serologías
#29	AnnotatorNotes T36	C0036743; Serologic tests; Laboratory Procedure
T37	PROC 180 204	regímenes de tratamiento
T38	DISO 280 302	tromboembolismo venoso
#30	AnnotatorNotes T38	C1861172; Venous Thromboembolism; Disease or Syndrome
T39	ANAT 919 938	células plasmáticas
#31	AnnotatorNotes T39	C0032112; Plasma Cells; Cell
T40	DISO 1162 1164	MM
T41	CHEM 1538 1552	anticoagulante
#32	AnnotatorNotes T41	C0003280; Anticoagulants; Pharmacologic Substance
T42	DISO 1978 1981	VHC
#33	AnnotatorNotes T42	C0019196; Hepatitis C; Disease or Syndrome
T43	CHEM 1608 1622	anticoagulante
#34	AnnotatorNotes T43	C0003280; Anticoagulants; Pharmacologic Substance
T44	PROC 1712 1715	ALT
#35	AnnotatorNotes T44	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T45	PROC 1722 1733	bilirrubina
#36	AnnotatorNotes T45	C0863174; Blood bilirubin measurement; Laboratory Procedure
T46	CHEM 1793 1803	creatinina
#37	AnnotatorNotes T46	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T47	ANAT 1831 1839	arterial
#38	AnnotatorNotes T47	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T48	PROC 1856 1882	tensión arterial sistólica
#39	AnnotatorNotes T48	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T49	ANAT 1864 1872	arterial
#40	AnnotatorNotes T49	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T50	PROC 1897 1924	tensión arterial diastólica
#41	AnnotatorNotes T50	C1305849; Diastolic blood pressure measurement; Diagnostic Procedure
T51	ANAT 1905 1913	arterial
#42	AnnotatorNotes T51	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
T52	DISO 1965 1968	VIH
#43	AnnotatorNotes T52	C0458074; Human immunodeficiency virus (HIV) status; Finding
T53	Date 12 16	2017
T54	LIVB 86 95	pacientes
#44	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T56	Age 337 355	entre 18 y 70 años
T57	LIVB 359 371	Sexos: ambos
#45	AnnotatorNotes T57	C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T58	LIVB 378 386	paciente
#46	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 479 485	sujeto
#47	AnnotatorNotes T59	C0681850; Study Subject; Group
T60	LIVB 492 511	representante legal
#48	AnnotatorNotes T60	C4288823; Legal Representative for the Study; Human
T61	LIVB 693 702	pacientes
#49	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 879 888	Pacientes
#50	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T64	Neg_cue 1202 1204	No
T65	LIVB 1254 1276	Mujeres en edad fértil
#51	AnnotatorNotes T65	C4324275; Woman of childbearing potential; Population Group
T66	Age 1265 1276	edad fértil
T68	Neg_cue 1281 1283	no
T69	PHYS 1363 1380	lactancia materna
#52	AnnotatorNotes T69	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T70	Spec_cue 1491 1500	riesgo de
T72	PHYS 1856 1872	tensión arterial
#53	AnnotatorNotes T72	C0005823; Blood Pressure; Organism Function
T73	PHYS 1897 1913	tensión arterial
#54	AnnotatorNotes T73	C0005823; Blood Pressure; Organism Function
T77	PHYS 1346 1357	embarazadas
#55	AnnotatorNotes T77	C0032961; Pregnancy; Organism Function
T55	ANAT 296 302	venoso
#56	AnnotatorNotes T55	C0042449; Veins; Body Part, Organ, or Organ Component | C1278960; Entire vein; Body Part, Organ, or Organ Component
T79	PHYS 583 592	entienden
#57	AnnotatorNotes T79	C0162340; Comprehension; Mental Process
T63	Duration 1649 1667	inferior a 6 meses
T67	PROC 443 461	performance status
#58	AnnotatorNotes T67	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T71	LIVB 1373 1380	materna
#59	AnnotatorNotes T71	C0026591; Mother (person); Family Group
A1	Assertion T23 Negated
A2	Assertion T24 Negated
A3	Population_data T65 Age
A4	Assertion T28 Speculated
A5	Status T22 History_of
A6	Status T26 History_of
A7	Assertion T31 Contraindicated
A8	Assertion T43 Contraindicated
#60	AnnotatorNotes T6	C5544470; Immunomodulating Agents; Pharmacologic Substance
#61	AnnotatorNotes T17	C0024419; Waldenstrom Macroglobulinemia; Neoplastic Process 
#62	AnnotatorNotes T20	C2585107; Asymptomatic multiple myeloma; Neoplastic Process 
#63	AnnotatorNotes T40	C0026764; Multiple Myeloma; Neoplastic Process
#64	AnnotatorNotes T31	C0199242; Administration of prophylactic anticoagulant; Therapeutic or Preventive Procedure 
T74	Observation 1080 1091	significado
A9	Assertion T74 Speculated
#65	AnnotatorNotes T74	C2826293; Clinical Significance; Finding
T75	Spec_cue 1092 1100	incierto
T76	Quantifier_or_Qualifier 1326 1332	eficaz
A10	Assertion T76 Negated
R1	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T76	
R2	Negation Arg1:T68 Arg2:T24	
R3	Negation Arg1:T68 Arg2:T76	
R4	Speculation Arg1:T75 Arg2:T74	
#66	AnnotatorNotes T76	C1704419; Effective; Qualitative Concept
R5	Used_for Arg1:T2 Arg2:T1	
#67	AnnotatorNotes T1	C0199242; Administration of prophylactic anticoagulant; Therapeutic or Preventive Procedure
R6	Experiences Arg1:T54 Arg2:T1	
R7	Experiences Arg1:T54 Arg2:T3	
T78	Quantifier_or_Qualifier 120 137	nuevo diagnóstico
#68	AnnotatorNotes T78	C1518321; Newly Diagnosed; Qualitative Concept
R8	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T78	
R9	Experiences Arg1:T54 Arg2:T5	
R10	Used_for Arg1:T6 Arg2:T37	
R11	Experiences Arg1:T54 Arg2:T37	
R12	Location_of Arg1:T55 Arg2:T38	
R13	Before Arg1:T7 Arg2:T38	
T80	Result_or_Value 468 470	≤2
T81	CONC 401 435	Eastern Cooperative Oncology Group
#69	AnnotatorNotes T81	C1520224; ECOG performance status; Intellectual Product
T82	CONC 437 441	ECOG
#70	AnnotatorNotes T82	C1520224; ECOG performance status; Intellectual Product
R14	Has_Result_or_Value Arg1:T81 Arg2:T80	
R15	Has_Result_or_Value Arg1:T82 Arg2:T80	
R16	Experiences Arg1:T58 Arg2:T67	
R17	Used_for Arg1:T82 Arg2:T67	
R18	Used_for Arg1:T81 Arg2:T67	
R19	Overlap Arg1:T8 Arg2:T79	
R20	Overlap Arg1:T9 Arg2:T79	
R21	Overlap Arg1:T79 Arg2:T10	
R22	Experiences Arg1:T59 Arg2:T79	
R23	Experiences Arg1:T60 Arg2:T79	
R24	Experiences Arg1:T59 Arg2:T10	
T83	Observation 641 685	están de acuerdo en participar en el estudio
R25	Overlap Arg1:T8 Arg2:T83	
R26	Overlap Arg1:T9 Arg2:T83	
R27	Before Arg1:T83 Arg2:T10	
R28	Experiences Arg1:T61 Arg2:T12	
R29	Experiences Arg1:T61 Arg2:T13	
T84	Quantifier_or_Qualifier 730 737	de novo
#71	AnnotatorNotes T84	C1515568; de novo; Idea or Concept
R30	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T84	
T85	PROC 1191 1198	estudio
#72	AnnotatorNotes T85	C0008976; Clinical Trials; Research Activity
R31	Before Arg1:T22 Arg2:T85	
R32	Negation Arg1:T64 Arg2:T23	
R33	Has_Age Arg1:T65 Arg2:T66	
R34	Experiences Arg1:T65 Arg2:T24	
R35	Experiences Arg1:T65 Arg2:T77	
R36	Experiences Arg1:T65 Arg2:T69	
R37	Experiences Arg1:T71 Arg2:T69	
T86	Quantifier_or_Qualifier 1381 1387	activa
#73	AnnotatorNotes T86	C0205177; Active; Qualitative Concept |C0679217; Active State; Idea or Concept
R38	Has_Quantifier_or_Qualifier Arg1:T69 Arg2:T86	
T87	Quantifier_or_Qualifier 1391 1399	Grado ≥2
R39	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T87	
#74	AnnotatorNotes T26	C1861172; Venous Thromboembolism; Disease or Syndrome
R40	Speculation Arg1:T70 Arg2:T28	
T88	Quantifier_or_Qualifier 1477 1483	activa
#75	AnnotatorNotes T88	C0205177; Active; Qualitative Concept |C0679217; Active State; Idea or Concept
R41	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T88	
T89	Observation 1486 1500	alto riesgo de
#76	AnnotatorNotes T89	C0332167; High risk of; Finding
R42	Before Arg1:T89 Arg2:T28	
R43	Used_for Arg1:T41 Arg2:T29	
R44	Used_for Arg1:T30 Arg2:T29	
R45	Used_for Arg1:T43 Arg2:T31	
T90	CONC 1626 1648	Supervivencia estimada
#77	AnnotatorNotes T90	C0023671; Life Expectancy; Group Attribute
R46	Has_Duration_or_Interval Arg1:T90 Arg2:T63	
T91	Result_or_Value 1697 1707	<50 x109/L
R47	Has_Result_or_Value Arg1:T32 Arg2:T91	
T92	Quantifier_or_Qualifier 1687 1695	moderada
#78	AnnotatorNotes T92	C0205081; Moderate (severity modifier); Qualitative Concept
R48	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T92	
T93	Result_or_Value 1716 1719	>3x
R49	Has_Result_or_Value Arg1:T44 Arg2:T93	
T94	Result_or_Value 1734 1773	>2x del valor superior de la normalidad
R50	Has_Result_or_Value Arg1:T45 Arg2:T94	
T95	Result_or_Value 1804 1814	<30 mL/min
R51	Has_Result_or_Value Arg1:T34 Arg2:T95	
R52	Location_of Arg1:T47 Arg2:T35	
T96	Quantifier_or_Qualifier 1840 1854	mal controlada
#79	AnnotatorNotes T96	C3853134; Poorly controlled; Functional Concept
R53	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T96	
R54	Location_of Arg1:T49 Arg2:T72	
R55	Location_of Arg1:T49 Arg2:T48	
T97	Result_or_Value 1883 1892	>200 mmHg
R57	Has_Result_or_Value Arg1:T48 Arg2:T97	
R58	Location_of Arg1:T51 Arg2:T73	
R59	Location_of Arg1:T51 Arg2:T50	
T98	Result_or_Value 1925 1934	>100 mmHg
R61	Has_Result_or_Value Arg1:T50 Arg2:T98	
T99	Result_or_Value 1950 1959	positivas
#80	AnnotatorNotes T99	C1446409; Positive; Finding
R67	Has_Result_or_Value Arg1:T36 Arg2:T99	
R68	Causes Arg1:T52 Arg2:T99	
R69	Causes Arg1:T33 Arg2:T99	
R70	Causes Arg1:T42 Arg2:T99	
R71	Before Arg1:T8 Arg2:T10	
R72	Before Arg1:T9 Arg2:T10	
T100	Quantifier_or_Qualifier 792 800	efectivo
#81	AnnotatorNotes T100	C1280519; Effectiveness; Qualitative Concept
R73	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T100	
R74	Experiences Arg1:T62 Arg2:T16	
R75	Experiences Arg1:T62 Arg2:T17	
R76	Experiences Arg1:T62 Arg2:T18	
R77	Experiences Arg1:T62 Arg2:T19	
R78	Location_of Arg1:T39 Arg2:T16	
R79	Before Arg1:T1 Arg2:T3	
#82	AnnotatorNotes T37	C1276413; Therapeutic regimen; Therapeutic or Preventive Procedure
#83	AnnotatorNotes T83	C1302239; Patient consented to clinical trial; Finding
A11	Experiencer T54 Patient
A12	Status T5 Future
A13	Status T37 Future
A14	Status T6 Future
A15	Experiencer T57 Patient
A16	Experiencer T58 Patient
A17	Experiencer T59 Patient
A18	Experiencer T60 Other
A19	Experiencer T61 Patient
A20	Status T14 Future
A21	Experiencer T62 Patient
A23	Experiencer T65 Patient
A24	Experiencer T71 Patient
